A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia

CompletedOBSERVATIONAL
Enrollment

10,877

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

November 3, 2021

Study Completion Date

May 31, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

Combination drug containing fimasartan and statins

"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"

Trial Locations (1)

42

Chonnam National University Hospital, Gwangju

All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY